Low VW Activity in Adolescent HMB
This is a research study for patients diagnosed with heavy menstrual bleeding (HMB) and low Von Willebrand Factor (VWF). Menstruation, also known as a period, is the regular discharge of blood and tissues from the uterus. HMB is having a heavier amount of discharge during menstrual period. Low Von Willebrand Factor means that the participant has lower level of a blood protein that is important for clotting of blood and so, the participant is at a higher risk for bleeding. The purpose of this project is to study the genetic differences of adolescent females with HMB and low VWF activity and compare the genetic differences with their bleeding manifestations, response to medications and outcome.
- Von Willebrand Factor Deficiency
- Eligible Ages
- Under 21 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Post-menarchal females less than 21 years of age
- HMB defined as PBAC score greater than 100
- VWF:Activity more than or equal to 30 and less than or equal to 50 IU/dL x 2
- VWF: Activity /VWF:Ag ratio greater than or equal to 0.6
- Normal VW multimers, if performed
- Post menarchal females age greater than or equal to 21 years
- VWF: Activity less than 30 or greater than 50 IU/dL consistently, type 2 or type 3 VWD
- Presence of other bleeding disorders (thrombocytopenia, platelet function defect, coagulation factor deficiency, fibrinogen defect or deficiency)
- Study Type
- Observational Model
- Time Perspective
|Group A||Adolescent women with heavy menstrual bleeding and low von willebrand factor activity.||
- NCT ID
- Baylor College of Medicine
Study ContactLakshmi V Srivaths, MD
One hundred and twenty subjects will be enrolled. Adolescent females with heavy menstrual bleeding (HMB) and low Von Willebrand Factor (VWF) will be recruited.
Data collection will occur from participant's medical records in regards to their low VWF activity and HMB medical history.
Participants will be asked to complete symptom questionnaires in regards to their HMB.
A blood sample will be collected to analyze how many participants have the disease causing sequence variation in the VWF gene and other genes affecting bleeding, clotting and blood vessel biology and correlated with their bleeding history.
The blood sample will be deidentified and stored indefinitely for future research.